Cytokines, tumour-cell death and immunogenicity: a question of choice.

[1]  G. Forni,et al.  Ultrastructural evidence of the mechanisms responsible for interleukin‐4‐activated rejection of a spontaneous murine adenocarcinoma , 2009, International journal of cancer.

[2]  P. Musiani,et al.  Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. , 1995, Journal of immunology.

[3]  M. Battegay,et al.  Fibroblasts as efficient antigen-presenting cells in lymphoid organs. , 1995, Science.

[4]  P. Musiani,et al.  5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. , 1995, Journal of immunology.

[5]  G. Forni,et al.  Co‐expression of B7‐1 and ICAM‐1 on tumors is required for rejection and the establishment of a memory response , 1995, European journal of immunology.

[6]  K. Zatloukal,et al.  Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. , 1995, Journal of immunology.

[7]  I. Schmidt-Wolf,et al.  Cytokines and gene therapy. , 1995, Immunology today.

[8]  P. Musiani,et al.  An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. , 1994, Journal of immunology.

[9]  M. Matsuda,et al.  Interleukin 10 pretreatment protects target cells from tumor- and allo- specific cytotoxic T cells and downregulates HLA class I expression , 1994, The Journal of experimental medicine.

[10]  P. Lollini,et al.  Immunizing and Curative Potential of Replicating and Nonreplicating Murine Mammary Adenocarcinoma Cells Engineered with Interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, Tumor Necrosis Factor α, Granulocyte-Macrophage Colony-stimulating Factor, and γ-Interferon Gene or Admixed with Conventional Adjuvants , 1994 .

[11]  P. Musiani,et al.  IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells. , 1994, Journal of immunology.

[12]  M. Colombo,et al.  Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? , 1994, Immunology today.

[13]  J. Mulé,et al.  Experimental and clinical studies of cytokine gene-modified tumor cells. , 1994, Human gene therapy.

[14]  P. Musiani,et al.  Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[15]  R. Derynck,et al.  Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. , 1993, Cancer research.

[16]  P. Musiani,et al.  Inhibition of tumor growth and enhancement of metastasis after transfection of the γ‐interferon gene , 1993 .

[17]  R. Weichselbaum,et al.  Footprinting of individual tumors and their variants by constitutive cytokine expression patterns. , 1993, Cancer research.

[18]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[19]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[20]  R. Foà,et al.  IL2 treatment for cancer: from biology to gene therapy. , 1992, British Journal of Cancer.

[21]  G. Forni,et al.  Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. , 1992, Journal of immunology.

[22]  M. Colombo,et al.  Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. , 1992, Cancer research.

[23]  M. Sporn,et al.  Cytokines in context , 1991, The Journal of cell biology.

[24]  M. Colombo,et al.  Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo , 1991, The Journal of experimental medicine.

[25]  P. Lollini,et al.  In vivo and in vitro production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding. , 1989, European journal of cancer & clinical oncology.

[26]  Allan H. Smith,et al.  Subversion of immune system by tumor cells and role of prostaglandins. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Baldwin Rw.  Immunity to Methylcholanthrene-Induced Tumours in Inbred Rats Following Atrophy and Regression of the Implanted Tumours , 1955 .

[28]  Foley Ej.  Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. , 1953 .

[29]  P. Musiani,et al.  Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[30]  G. Dranoff,et al.  Gene transfer as cancer therapy. , 1995, Advances in immunology.

[31]  M. Colombo,et al.  Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions. , 1994, Folia biologica.

[32]  A. Gearing,et al.  Clinical applications of cytokines : role in pathogenesis, diagnosis, and therapy , 1993 .

[33]  A. Mantovani,et al.  Tumor-associated macrophages. , 1989, Current opinion in immunology.